SCHEMBL1709614

SCHEMBL1709614

O=C(Nc1ccc(Cl)cn1)C(Sc1ccc(F)cc1)c1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FFAR2 O15552 1/20 0.56
SMN1; SMN2 Q16637 5/20 0.53
RAB9A P51151 3/20 0.53
KMT2A Q03164 2/20 0.53
LMNA P02545 1/20 0.53
BRD4 O60885 1/20 0.49
ALDH1A1 P00352 2/20 0.47
NPC1 O15118 2/20 0.47
TSHR P16473 2/20 0.47
PKM P14618 1/20 0.47
L3MBTL1 Q9Y468 5/20 0.47
TDP1 Q9NUW8 2/20 0.46
MAPK1 P28482 1/20 0.45
PTK2 Q05397 1/20 0.45
MEN1 O00255 1/20 0.45
HTT P42858 1/20 0.45
GRM5 P41594 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL935450 1.00 FFAR2 (0.56) FFAR2SMN1; SMN2RAB9AKMT2ALMNA
Hydrochloric Acid SCHEMBL933845 0.99 FFAR2 (0.55) FFAR2SMN1; SMN2RAB9AKMT2ALMNA
SCHEMBL1709594 0.94 L3MBTL1 (0.53) FFAR2SMN1; SMN2RAB9AKMT2ALMNA
Hydrochloric Acid SCHEMBL933932 0.93 L3MBTL1 (0.51) FFAR2SMN1; SMN2RAB9AKMT2ALMNA
SCHEMBL1709608 0.91 FFAR2 (0.52) FFAR2SMN1; SMN2RAB9AKMT2ALMNA
Hydrochloric Acid SCHEMBL934058 0.90 FFAR2 (0.51) FFAR2SMN1; SMN2RAB9AKMT2ALMNA
SCHEMBL933295 0.88 SMN1; SMN2 (0.57) FFAR2SMN1; SMN2RAB9AKMT2AALDH1A1
SCHEMBL934170 0.88 NPSR1 (0.56) SMN1; SMN2RAB9AKMT2ALMNAALDH1A1
Hydrochloric Acid SCHEMBL1286268 0.87 SMN1; SMN2 (0.56) FFAR2SMN1; SMN2RAB9AKMT2AALDH1A1
SCHEMBL1709535 0.85 RAB9A (0.49) FFAR2SMN1; SMN2RAB9AKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088800-A1 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS ALLERGAN, INC. (US) 2012-04-12 US disclosed
WO-2011008475-A1 OPTIONALLY SUBSTITUTED 2-(ARYLMETHYL, ARYLOXY OR ARYLTHIO) -N- PYRIDIN-2 -YL-ARYL ACETAMIDE OR 2, 2-BIS (ARYL) -N-PYRIDIN-2-YL ACETAMIDE COMPOUNDS AS MEDICAMENTS FOR THE TREATMENT OF EYE DISEASES ALLERGAN, INC. (US) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088800-A1 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS S1PR3, S1PR5, S1PR1 FFAR2 117/4885SMN1; SMN2 3896/4885RAB9A 2924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.